Q1 2025 Management View CEO Rick Stewart stated that "Achieve is on track to submit the NDA for cytisinicline next month." He emphasized that "all internal resources are now focused on a successful ...
On-track progress for the New Drug Application (NDA) for paltusotine, with a PDUFA target action date set for September 25, 2025, indicating strong engagement with the FDA. Marketing authorization ...
Singh maintained guidance that "we'll see top line results released before the end of this calendar quarter, so by the end of this calendar year" for PALISADE-3. Singh projected that top line results ...
TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, ...
The FDA issued a complete response letter to Aldeyra Therapeutics Inc's (NASDAQ:ALDX) New Drug Application (NDA) of reproxalap, an investigational drug candidate for dry eye disease. Although no ...
TUCSON, Ariz. (KVOA) - Tucson City Council is set to discuss potential reforms to the city's use of non-disclosure agreements (NDAs) in an upcoming study session. The Tucson City Council study session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results